20.66
-0.55 (-2.59%)
Previous Close | 21.21 |
Open | 20.27 |
Volume | 746,622 |
Avg. Volume (3M) | 1,034,690 |
Market Cap | 1,371,958,272 |
Price / Sales | 236.81 |
Price / Book | 2.09 |
52 Weeks Range | |
Earnings Date | 5 Nov 2025 |
Operating Margin (TTM) | -9,027.19% |
Diluted EPS (TTM) | -2.70 |
Quarterly Revenue Growth (YOY) | 345.50% |
Total Debt/Equity (MRQ) | 0.49% |
Current Ratio (MRQ) | 21.67 |
Operating Cash Flow (TTM) | -171.51 M |
Levered Free Cash Flow (TTM) | -101.09 M |
Return on Assets (TTM) | -16.88% |
Return on Equity (TTM) | -23.20% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Celldex Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | 2.0 |
Technical Moving Averages | -2.5 |
Technical Oscillators | -2.5 |
Average | -0.38 |
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Growth |
% Held by Insiders | 0.32% |
% Held by Institutions | 113.13% |
52 Weeks Range | ||
Median | 50.00 (142.01%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 16 Jun 2025 | 50.00 (142.01%) | Buy | 20.34 |
13 Jun 2025 | 50.00 (142.01%) | Buy | 21.26 |
No data within this time range.
Date | Type | Details |
---|---|---|
07 Aug 2025 | Announcement | Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
14 Jun 2025 | Announcement | Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 |
12 Jun 2025 | Announcement | Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 |
10 Jun 2025 | Announcement | Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress |
06 Jun 2025 | Announcement | Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |